JMJeaustin Mora-Jiménez

Jeaustin Mora-Jiménez

*This is an algorithmically generated author record based on publicly available information.

Jeaustin Mora-Jiménez has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmaceutical Indication and Pharmacist Prescribing in Primary Care: An International Comparative Characterization of Regulatory Models, Clinical Scope, and Evidence Synthesis

    by Esteban Zavaleta-Monestel, Luis Carlos Monge-Bogantes, Andreina Hernandez-Cordonero, Kevin Cruz-Mora, Sofia Segura-Cano, Yajaira Quesada-Rojas, José Gatgens-Gomez, Sebastian Arguedas-Chacón, José Andrés Castro-Gamboa, Jeaustin Mora-Jiménez

    Pharmaceutical indication and pharmacist prescribing are distinct mechanisms through which community pharmacists can contribute to primary care, particularly in managing minor symptoms and low-complexity conditions. This narrative review critically compared scientific, regulatory, and institutional sources identified through PubMed/MEDLINE, ScienceDirect, Google Scholar, and consultation of regulatory and professional documents. Domains of the Scale for the Assessment of Narrative Review Articles (SANRA) informed appraisal of the manuscript, rather than source selection or assessment of individual studies. Four recurrent analytical configurations were identified: pharmaceutical indication, protocol-based medicine supply or prescribing, collaborative prescribing, and independent prescribing. Their legal bases, clinical scopes, medicine-access mechanisms, and implementation requirements differ between and within jurisdictions. In the examples reviewed, structured services variously specify eligibility criteria, red-flag assessment, safety-netting, referral, documentation, and coordination with other healthcare professionals. Heterogeneous study designs and outcome measures limit comparisons of clinical effectiveness, safety, service utilization, and costs; no universal hierarchy among regulatory configurations can be established. In selected Latin American settings, including Costa Rica, pharmaceutical consultation and indication are documented, although formalization varies. Future research should prioritize comparable definitions, standardized outcomes, and sustainability.

  • Open Access

    Comparative Cardiac Adverse-Event Reporting Patterns Across Antineoplastic Therapeutic Classes: A Global Analysis Using WHO VigiAccess

    by Esteban Zavaleta-Monestel, Jeaustin Mora-Jiménez, Jorge Arturo Villalobos-Madriz, Kevin Tencio-Morales, Brandon Enríquez-Gutiérrez, José Andrés Castro Gamboa, Sebastián Arguedas-Chacón

    Background/Objectives: Cardiac adverse-event reports for antineoplastic agents may differ across regulatory coding categories, affecting disproportionality estimates. We compared anthracyclines, human epidermal growth factor receptor 2 (HER2)-targeted agents, and vascular endothelial growth factor (VEGF) inhibitors. Methods: We analyzed aggregated World Health Organization VigiAccess data retrieved on March 23, 2026, for eight drugs in three classes. Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class and cardiac Preferred Term distributions were described; reporting odds ratios (RORs) with 95% confidence intervals (CIs) were calculated using a restricted antineoplastic comparator cohort. Pairwise within-cohort comparators and cardiac/vascular outcomes were explored; an external database-wide comparison was not feasible. Results: Across 389,068 drug-specific report observations, anti-HER2 agents had the highest proportion classified under Cardiac disorders (10.43%) and the strongest class-level ROR (2.04; 95% CI 1.99–2.10); trastuzumab had the highest drug-level ROR (2.22; 2.16–2.29). Anthracyclines contributed the most cardiac reports (11,273), whereas anti-VEGF agents showed greater proportional reporting in vascular disorders (10.86%) and prominent myocardial infarction reports among cardiac Preferred Terms. Exploratory analyses demonstrated sensitivity to comparator composition and outcome definition. Conclusions: Reporting patterns varied across classes, but these findings do not establish incidence, causality, comparative clinical risk, or independent grounds for changing surveillance protocols.

  • Open Access

    Pharmaceutical Indication and Pharmacist Prescribing in Primary Care: An International Comparative Characterization of Regulatory Models, Clinical Scope, and Evidence Synthesis

    by Esteban Zavaleta-Monestel, Luis Carlos Monge-Bogantes, Andreina Hernandez-Cordonero, Kevin Cruz-Mora, Sofia Segura-Cano, Yajaira Quesada-Rojas, Jose Gatgens-Gomez, Sebastian Arguedas-Chacón, José Andrés Castro-Gamboa, Jeaustin Mora-Jiménez

    Pharmaceutical indication and pharmacist prescribing have become strategies for expanding the capacity of primary care, particularly in the management of minor symptoms and low-complexity clinical conditions. This narrative review, guided by the SANRA domains, integrated scientific, regulatory, and institutional evidence identified through PubMed/MEDLINE, ScienceDirect, and Google Scholar, supplemented by grey literature from regulatory bodies, health services, and professional organizations, to comparatively characterize regulatory and practice models described across jurisdictions. Four main configurations were identified: pharmaceutical indication, protocol-based models, collaborative prescribing, and independent prescribing, with heterogeneous implementation internationally. Available evidence reports favorable outcomes in some services, including improved accessibility, high user satisfaction, and a potential shift in consultations from other healthcare settings to community pharmacy; however, heterogeneity in study designs, settings, and outcome measures, together with the predominance of observational and implementation studies, limits the certainty of these findings. Rather than demonstrating the superiority of a particular level of professional autonomy, the literature consistently shows that structured models incorporate clinical protocols, eligibility criteria, red-flag assessment, safety-netting, referral, and documentation. Effective implementation also requires consideration of professional training, care integration, documentation systems, and sustainable funding mechanisms. In Latin America and Costa Rica, the literature documents frequent pharmaceutical consultation and indication practices, although with variable levels of formalization and standardization.

  • Open Access

    Private-Sector Sales Trends of Antidepressants and Antipsychotics in Costa Rica, 2022–2026: An Aggregate Analysis by Active Ingredient

    by Esteban Zavaleta-Monestel, Luis Herrera-Jiménez, Sebastian Arguedas-Chacón, Jose Castro-Gamboa, Kevin Cruz-Mora, Jeaustin Mora-Jiménez, Ricardo Millán-González

    Aggregated pharmaceutical sales data can characterize apparent medication consumption and changes in market composition, although they do not represent individual prescribing or patient exposure. This study described private-sector sales trends of antidepressants and antipsychotics in Costa Rica from moving annual total (MAT) February 2022 to MAT February 2026. An observational, descriptive, longitudinal study was conducted using aggregated IQVIA sales data. Total defined daily doses (DDDs) sold were analyzed as the primary indicator, complemented by units sold and analyses by therapeutic group and active ingredient. Antidepressant DDDs increased from 15,299,281 to 17,976,312 (+17.5%), whereas antipsychotic DDDs increased from 1,078,635 to 1,476,810 (+36.9%). In 2026, escitalopram and sertraline had the highest DDD volumes among antidepressants, while quetiapine was the leading antipsychotic. Desvenlafaxine was the largest contributor to net antidepressant growth, whereas aripiprazole and lurasidone contributed substantially to antipsychotic growth. Overall, private-sector sales of both therapeutic groups increased, with distinct patterns across active ingredients. These findings provide a baseline for pharmaceutical market surveillance but should not be interpreted as estimates of total national consumption, public-sector utilization, individual prescribing, clinical indications, or actual patient exposure.

  • Open Access

    Vaccine Dispensing Through Private Community Pharmacies in Costa Rica: A National Descriptive Analysis

    by Jeaustin Mora-Jiménez, Kevin Cruz-Mora, Sofia Segura-Cano, Yajaira Quesada-Rojas, Jose Gatgens-Gomez, Sebastian Arguedas-Chacón, Esteban Zavaleta-Monestel

    Background: Pharmacist involvement in immunization has expanded as a strategy to improve access to vaccines. In Costa Rica, private community pharmacies operate under a regulatory framework for vaccination services, yet evidence on private-market vaccine dispensing remains limited. The aim of this study was to characterize vaccine dispensing through private community pharmacies in Costa Rica by dispensed doses, economic value, vaccine category, and provincial distribution, comparing MAT February 2025 and MAT February 2026. Methods: A descriptive, retrospective, national study was conducted using an aggregated secondary IQVIA database of the Costa Rican private pharmaceutical market. Dispensed doses, economic value in USD, percentage variation, and share by vaccine category and province were analyzed; no individual patient, professional, establishment, or nominal vaccination records were used. Results: Dispensed doses increased from 162,664 to 217,387 (+33.6%), while economic value increased from USD 8,700,809 to USD 13,416,717 (+54.2%). Influenza accounted for the highest dispensing volume in MAT February 2026 (87,064 doses). Yellow fever showed the largest between-period increase, from 22,281 to 70,133 doses and from USD 2.7 million to USD 7.0 million. HPV ranked second in economic value (USD 3.6 million). San José accounted for 63.0% of dispensed doses and 52.9% of national private-market economic value. Conclusions: Private-market vaccine dispensing through Costa Rican community pharmacies was higher in MAT February 2026 than in MAT February 2025 in both dispensed doses and economic value, driven primarily by yellow fever. Influenza accounted for the highest dispensing volume, while HPV retained substantial economic weight. These findings characterize vaccine dispensing through the private community pharmacy market but do not establish vaccine administration, vaccination coverage, or clinical or epidemiological outcomes.

  • Infección urinaria febril por Escherichia coli productora de betalactamasa de espectro extendido (BLEE) en una lactante con fracaso del tratamiento empírico

    by Jorge Martinez Vasquez, Jeaustin Mora Jiménez, Kevin Cruz Mora, Esteban Zavaleta Monestel

    Las infecciones urinarias febriles causadas por enterobacterias productoras de betalactamasa de espectro extendido (BLEE) representan un desafío creciente en pediatría debido al incremento de la resistencia antimicrobiana y al riesgo de fracaso del tratamiento empírico.

  • Open Access

    Comparative Cardiac Adverse-Event Reporting Patterns Across Antineoplastic Therapeutic Classes: A Global Analysis Using WHO VigiAccess

    by Esteban Zavaleta-Monestel, Jeaustin Mora-Jiménez, Jorge Arturo Villalobos-Madriz, Kevin Tencio-Morales, Brandon Enríquez-Gutiérrez, José Andrés Castro Gamboa, Sebastián Arguedas-Chacón

    Background/Objectives: Antineoplastic therapies have improved cancer survival but remain a major source of treatment-related cardiotoxicity. Previous pharmacovigilance studies have largely focused on drug-specific cardiac signals or individual therapeutic pathways, whereas cross-class differences in cardiovascular reporting across MedDRA categories and their impact on disproportionality estimates remain less well characterized. We therefore compared cardiac adverse-event reporting patterns across anthracyclines, anti-HER2 agents, and anti-VEGF agents within a restricted antineoplastic comparator cohort. Methods: A retrospective pharmacovigilance study was conducted using aggregated ICSR data from VigiBase accessed through the public VigiAccess interface (March 23, 2026). Eight antineoplastic agents were grouped into three therapeutic classes. Descriptive analyses of demographic characteristics, System Organ Class (SOC) distributions, and cardiac Preferred Terms (PT) were performed. Reporting Odds Ratios (ROR) with 95% confidence intervals were calculated using a restricted antineoplastic comparator cohort. Signals were defined as a lower 95% CI bound >1 with at least five cardiac reports. Results: Across eight drug-specific VigiAccess queries, 389,068 drug-specific report observations were analyzed. Anti-HER2 agents showed the highest proportional cardiac-reporting burden (10.43%) and the strongest class-level disproportionality signal (ROR 2.04; 95% CI: 1.99–2.10), with trastuzumab showing the strongest individual-drug estimate (ROR 2.22; 95% CI: 2.16–2.29). Anthracyclines accounted for the largest number of cardiac reports (n = 11,273), with a reporting pattern dominated by myocardial-dysfunction Preferred Terms, led by cardiomyopathy and heart failure. Anti-VEGF agents showed greater reporting within the Vascular disorders (10.86%) and Renal and urinary disorders (6.08%) SOCs, with myocardial infarction among the most frequently reported cardiac PTs. Conclusions: Cardiac adverse event reporting for antineoplastic therapy follows class-specific patterns rather than a uniform profile. Anti-HER2 agents showed the highest proportion of reports classified under Cardiac disorders, anthracyclines the greatest absolute volume, and anti-VEGF therapies exhibited a distinct vascular–ischemic reporting profile. These reporting-based signals may support hypotheses regarding class-specific cardiovascular surveillance consistent with established cardio-oncology guidance, while highlighting both the value and the inherent limitations of global spontaneous-reporting pharmacovigilance data. These findings are hypothesis-generating and should be interpreted as reporting patterns rather than incidence estimates, comparative clinical risks, or causal effects. Spontaneous-reporting data remain susceptible to reporting bias, unmeasured confounding, and incomplete clinical information.

  • Open Access

    Contrast Media-Associated Nephrotoxicity: A Narrative Review of Pathophysiology, Risk Factors, Prevention, and Clinical Management

    by Esteban Zavaleta-Monestel, Jeaustin Mora-Jiménez, Kevin Cruz-Mora, Sebastián Arguedas-Chacón, Luis Guillermo Herrera-Jiménez, José Andrés Castro-Gamboa, José Miguel Chaverri-Fernández

    Background: Contrast media are essential tools in diagnostic and interventional imaging, but their relationship with acute kidney injury remains clinically relevant and conceptually debated. This narrative review aimed to synthesize current evidence on contrast media-associated nephrotoxicity, including terminology, epidemiology, pathophysiology, risk stratification, prevention, pharmacotherapeutic management, and clinical decision-making. Methods: A structured literature search was conducted in major biomedical databases and complemented by international guidelines and consensus statements addressing contrast-associated and contrast-induced acute kidney injury in adults exposed to intravascular contrast media. Discussion: Contemporary evidence emphasizes the distinction between contrast-associated acute kidney injury, which reflects a temporal association after exposure, and contrast-induced acute kidney injury, which implies causality. The renal risk directly attributable to modern intravenous iodinated contrast media appears to have been historically overestimated, although clinically relevant risk persists in vulnerable patients. Proposed mechanisms include renal vasoconstriction, medullary hypoxia, oxidative stress, mitochondrial dysfunction, tubular epithelial injury, endothelial dysfunction, and inflammatory or apoptotic pathways. Preventive strategies should be individualized, with isotonic saline remaining the main intervention when indicated, whereas routine pharmacologic prophylaxis is not supported by consistent clinically meaningful benefit. Conclusions: Renal safety in contrast-enhanced imaging requires a balanced approach that minimizes avoidable kidney injury in high-risk patients without unnecessarily delaying clinically indicated diagnostic or therapeutic procedures.

  • Open Access

    Artificial Intelligence in Psychiatry: Five Decades of Progress and Persistent Translational Challenges

    by Esteban Zavaleta‐Monestel, Luis Guillermo Herrera‐Jiménez, Sofía Suárez‐Sánchez, Sebastián Arguedas‐Chacón, Jeaustin Mora‐Jiménez, Ricardo Millán‐González

    Objective: This review examined the historical development of artificial intelligence (AI) in psychiatry from 1972 to 2025 and identified persistent barriers to clinical translation. Method: The review used a structured source‐identification approach across PubMed/MEDLINE, Web of Science, Google Scholar, ScienceDirect, citation tracking, and targeted historical searches. It synthesized sources qualitatively and organized them chronologically. A structured evidence table summarized representative milestones by era, AI paradigm, clinical task, data modality, validation approach, implementation status, and translational limitation. Results: Psychiatric AI evolved from symbolic simulation and rule‐based expert systems to connectionist models, supervised machine learning, computational psychiatry, digital phenotyping, multimodal monitoring, digital mental health tools, and large language models. Despite increasing computational sophistication, recurring barriers persisted, including uncertain target validity, diagnostic heterogeneity, limited external validation, poor transportability, interpretability challenges, workflow integration, equity, patient trust, and governance. Across eras, technical progress was cyclical rather than linear, with successive waves reproducing unresolved clinical and implementation challenges. Conclusions: The clinical impact of psychiatric AI will likely depend less on algorithmic novelty alone than on clearer clinical targets, prospective validation, implementation trials, patient‐centered evaluation, equity‐sensitive generalizability, and mental health–specific governance. Relevance to Clinical Practice: For routine psychiatric care, AI tools require evidence of clinical validity, transportability, workflow compatibility, patient acceptability, equity, and appropriate governance rather than technical performance alone.

  • Open Access

    Psychiatric Adverse Events Associated with GLP-1 Receptor Agonists: Evidence of Intraclass Heterogeneity in the WHO VigiBase Global Database

    by Esteban Zavaleta-Monestel, Sebastián Arguedas-Chácon, Jeaustin Mora-Jiménez, Jorge Arturo Villalobos-Madriz, Brandon Enríquez-Gutiérrez, Kevin Tencio-Morales

    Background/Objectives: Concerns regarding the psychiatric safety profile of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have increased since the 2023 European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) reviews. However, it remains unclear whether this signal is uniform across the drug class or concentrated in specific compounds. This study aimed to characterize and compare, in a systematic manner, the global reporting patterns of psychiatric adverse drug reactions (ADRs) associated with the main GLP-1 RAs using the World Health Organization (WHO) VigiBase global pharmacovigilance database. Methods: A descriptive, cross-sectional pharmacovigilance study was conducted on individual case safety reports (ICSRs) retrieved from VigiAccess (January 2000–2026) for semaglutide, liraglutide, dulaglutide, exenatide, tirzepatide, and lixisenatide. A disproportionality analysis was performed within the MedDRA “Psychiatric disorders” System Organ Class (SOC) using the Reporting Odds Ratio (ROR) with 95% confidence intervals (CIs). This study adhered to the STROBE and READUS-PV guidelines. Results: A total of 537,519 ADR reports were analyzed across the five drugs with sufficient reporting volume (lixisenatide was excluded owing to n = 22 psychiatric events). Psychiatric disorders accounted for 24,899 reports, with marked intraclass heterogeneity in both the proportion of psychiatric reports (6.73% for semaglutide versus 3.12% for tirzepatide) and in disproportionality estimates. Signals of disproportionate reporting were identified exclusively for semaglutide (ROR 1.55; 95% CI 1.50–1.59) and liraglutide (ROR 1.19; 95% CI 1.15–1.23), whereas tirzepatide, dulaglutide, and exenatide showed point estimates below unity. Conclusions: The psychiatric safety profile of GLP-1 RAs is not homogeneous within the therapeutic class. The disproportionality signal is concentrated on semaglutide and, to a lesser extent, liraglutide. These findings extend previous WHO-based analyses limited to suicidality and support active clinical surveillance of psychiatric symptoms in patients treated with these specific agents.